Sutro Biopharma, Inc.
STRO
$0.7991
-$0.0122-1.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 17.49% | 73.81% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 17.49% | 73.81% | |||
| Cost of Revenue | 101.36% | -371.31% | |||
| Gross Profit | -91.75% | 442.08% | |||
| SG&A Expenses | 46.99% | -36.99% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -18.98% | 4.75% | |||
| Operating Income | 27.26% | 3.92% | |||
| Income Before Tax | -8.39% | -43.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -4.87% | -48.49% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4.87% | -48.49% | |||
| EBIT | 27.26% | 3.92% | |||
| EBITDA | 28.11% | 4.13% | |||
| EPS Basic | -4.11% | -47.66% | |||
| Normalized Basic EPS | 22.19% | 3.86% | |||
| EPS Diluted | -4.11% | -47.66% | |||
| Normalized Diluted EPS | 22.19% | 3.86% | |||
| Average Basic Shares Outstanding | 0.72% | 0.57% | |||
| Average Diluted Shares Outstanding | 0.72% | 0.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||